Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

Blood

Volumn 97, Issue 5, 2001, Pages 1165-1171

  Stevens, Servi J C ^a   Verschuuren, Erik A M ^b   Pronk, Inge ^b   Van Der Bij, Wim ^b   Harmsen, Martin C ^b   The, T Hauw ^b   Meijer, Chris J L M ^b   Van Den Brule, Adriaan J C ^b   Middeldorp, Jaap M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; FOSCARNET SODIUM; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; LYMPHOCYTE FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MALE; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; VIRUS LOAD; VIRUS REPLICATION;

EID: 0035283115     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1165     Document Type: Article

References (31)

1. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders: ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting
2. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantation
3. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients
4. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection respending to acyclovir and reduction in immune suppression
5. Lymphoproliferative disorders following organ transplantation: Clinical syndromes and treatment options
6. Molecular pathology of posttransplant lymphoproliferative disorders
7. Epstein-Barr virus
8. Posttransplant lymphoproliferative disorders: Summary of society for hematopathology workshop
9. Detection of hetereogeneous Epstein-Barr virus gene expression patterns within individual posttransplantation lymphoproliferative disorders
10. Presence of Epstein-Barr-virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS-related lymphomas
11. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative disease: Implications for understanding their pathogenesis and developing rational treatment strategies
12. Rejection in human grafts
13. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression
14. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
15. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
16. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant recipients and risk of lymphoproliferative disease
17. Serial measurement of Epstein-Barr virus load in peripheral blood in pediatric liver transplant recipients during treatment for postransplant lymphoproliferative disease
18. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease
19. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation
20. Rapid and simple method for purification of nucleic acids
21. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR
22. Detection and quantification of latently infected B lyrephocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction
23. Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder
24. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pedi attic transplant recipients with lymphoproliferative disorders
25. The use of general primer GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction
26. Avoiding false-positives with PCR
27. Presence of Epstein-Barr virus harbouring small and intermediate sized cells in Hodgkin's disease: Is there a relationship with Reed-Stemberg cells?
28. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immuno-compromised patients
29. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children
30. Epstein-Barr virus (EBV) specific cytotoxic T cells measured by flow cytometry and quantitative EBV PCR in posttransplant lymphoproliferatire disease (PTLD)
31. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients